JP2020537652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537652A5 JP2020537652A5 JP2020521444A JP2020521444A JP2020537652A5 JP 2020537652 A5 JP2020537652 A5 JP 2020537652A5 JP 2020521444 A JP2020521444 A JP 2020521444A JP 2020521444 A JP2020521444 A JP 2020521444A JP 2020537652 A5 JP2020537652 A5 JP 2020537652A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- pharmaceutically acceptable
- acceptable salt
- oligonucleotide conjugate
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 12
- -1 monomethoxytrityl Chemical group 0.000 claims description 12
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 125000004434 sulfur atom Chemical group 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 8
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 208000029578 Muscle disease Diseases 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 229930024421 Adenine Natural products 0.000 claims description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000643 adenine Drugs 0.000 claims description 4
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 150000001945 cysteines Chemical class 0.000 claims description 4
- 229940104302 cytosine Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 229940113082 thymine Drugs 0.000 claims description 4
- 229940035893 uracil Drugs 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 241000725619 Dengue virus Species 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 241001115401 Marburgvirus Species 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000001767 chemoprotection Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 235000011962 puddings Nutrition 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 0 CC(C)N1CC(*)OC(C)C1 Chemical compound CC(C)N1CC(*)OC(C)C1 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PVMNSAIKFPWDQG-UHFFFAOYSA-N CC(C)(C)N1CCNCC1 Chemical compound CC(C)(C)N1CCNCC1 PVMNSAIKFPWDQG-UHFFFAOYSA-N 0.000 description 1
- QJQUFJQKQQYYHZ-UHFFFAOYSA-N CC(C)c(c(F)c(c(-c(c([I]=C)c(c(C(C)C)c1F)F)c1[I]=C)c1F)F)c1F Chemical compound CC(C)c(c(F)c(c(-c(c([I]=C)c(c(C(C)C)c1F)F)c1[I]=C)c1F)F)c1F QJQUFJQKQQYYHZ-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023129042A JP2023138661A (ja) | 2017-10-17 | 2023-08-08 | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573473P | 2017-10-17 | 2017-10-17 | |
| US62/573,473 | 2017-10-17 | ||
| PCT/US2018/056178 WO2019079367A1 (en) | 2017-10-17 | 2018-10-17 | OLIGONUCLEOTIDE CONJUGATES-BICYCLIC PEPTIDES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129042A Division JP2023138661A (ja) | 2017-10-17 | 2023-08-08 | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537652A JP2020537652A (ja) | 2020-12-24 |
| JP2020537652A5 true JP2020537652A5 (enExample) | 2021-11-11 |
| JP7356416B2 JP7356416B2 (ja) | 2023-10-04 |
Family
ID=66173478
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521444A Active JP7356416B2 (ja) | 2017-10-17 | 2018-10-17 | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
| JP2023129042A Pending JP2023138661A (ja) | 2017-10-17 | 2023-08-08 | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129042A Pending JP2023138661A (ja) | 2017-10-17 | 2023-08-08 | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3700537A4 (enExample) |
| JP (2) | JP7356416B2 (enExample) |
| TW (1) | TWI816703B (enExample) |
| WO (1) | WO2019079367A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3983794B1 (en) * | 2019-06-14 | 2025-10-22 | Laboratory Corporation of America Holdings | Ion-pairing free lc-ms bioanalysis of oligonucleotides |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035799T2 (en) * | 2006-05-10 | 2018-05-28 | Sarepta Therapeutics Inc | Cationic oligonucleotide analogues containing subunits |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP4074694A1 (en) * | 2011-10-27 | 2022-10-19 | Massachusetts Institute Of Technology | Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof |
| US10111962B2 (en) * | 2012-09-25 | 2018-10-30 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| WO2014124952A1 (en) * | 2013-02-12 | 2014-08-21 | Syddansk Universitet | "clickable" alkyne-lna oligonucleotides |
| EP3297649B1 (en) * | 2015-05-19 | 2023-10-11 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| WO2017066789A1 (en) * | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
-
2018
- 2018-10-17 WO PCT/US2018/056178 patent/WO2019079367A1/en not_active Ceased
- 2018-10-17 EP EP18868378.3A patent/EP3700537A4/en active Pending
- 2018-10-17 JP JP2020521444A patent/JP7356416B2/ja active Active
- 2018-10-17 TW TW107136579A patent/TWI816703B/zh active
-
2023
- 2023-08-08 JP JP2023129042A patent/JP2023138661A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537654A5 (enExample) | ||
| JP2018538302A5 (enExample) | ||
| HRP20231431T1 (hr) | Peptidno oligonukleotidni konjugati | |
| JP5271913B2 (ja) | 化合物 | |
| JP2020503009A5 (enExample) | ||
| JP2021182946A5 (enExample) | ||
| US7582748B2 (en) | Methods of manufacture of 2′-deoxy-β-L-nucleosides | |
| JP2025096427A (ja) | 抗ウイルスプロドラッグ及びその製剤 | |
| JP2020503010A5 (enExample) | ||
| JP2018509143A5 (enExample) | ||
| AU780879B2 (en) | Anti-viral pyrimidine nucleoside analogues | |
| CA2904692A1 (en) | Modified 4'-nucleosides as antiviral agents | |
| JP2019514426A5 (enExample) | ||
| WO2005021568B1 (en) | Novel tricyclic nucleosides or nucleotides as therapeutic agents | |
| RU2005118421A (ru) | 2'-разветвленные нуклеозиды и мутация flaviviridae | |
| JP2009538829A5 (enExample) | ||
| JP2019088329A5 (enExample) | ||
| CN100335492C (zh) | 生产3’－核苷前体药物的方法 | |
| JP2024038025A (ja) | 癌療法のためのコンジュゲートの塩 | |
| CZ295706B6 (cs) | Derivát 5´-deoxycytidinu, způsob jeho výroby a použití a farmaceutická kompozice a kit s jeho obsahem | |
| JP2020525502A5 (enExample) | ||
| JP2020537652A5 (enExample) | ||
| EP0356166B1 (en) | Therapeutic nucleosides | |
| EP0672701A1 (de) | PNA-Synthese unter Verwendung einer basenlabilen Amino-Schutzgruppe | |
| KR890016059A (ko) | 포스포노알킬퓨린 유도체 |